Merrill Lynch reiterates buy for NeoPharm

NeoPharm Inc. was reiterated by Merrill Lynch analyst David Munno at a buy rating. The company is facing binary risk from the outcome of a phase III trial for IL13-PE38 for glioblastoma multiforme, however with the Precise trial nearing completion and the current stock price, Merrill Lynch believes the stock offers a favorable risk/reward and an attractive entry point. Shares of the Lake Forest, Ill.-based biopharmaceutical company were up $0.13, or 1.36%, at 9.69 on volume of 142,114 shares versus the three-month running average of 299,253 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.